Gail Boudreaux bought $2.4M of Elevance Health (ELV)
Executed Jul 18 2025, disclosed Jul 18 2025, the same day.
Over the 21 trading sessions from the disclosed entry session (Jul 18 2025), the stock returned +6.6% (delay-adjusted); from the execution session (Jul 18 2025), +6.6%. Derived: entry at the session's open, exit at the close 20 sessions later.
Gail Boudreaux (President and CEO) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Elevance Health, Inc. (ELV). Across 1 priced purchase filing, the average 21-session return was +7.2% from execution and +7.2% from disclosure (delay-adjusted; derived). The largest single filing was $1.0M of ELV (2,725 sh across 2 lots, as filed), executed Jul 17.
Healthcare · Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→2,725 sh across 2 lots
Exec Jul 17
Filed Jul 17 · 1:50 PM ET